![Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer | SpringerLink Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10549-020-05978-8/MediaObjects/10549_2020_5978_Fig3_HTML.png)
Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer | SpringerLink
![Comparison of two-dimensional gel electrophoresis patterns and MALDI-TOF MS analysis of therapeutic recombinant monoclonal antibodies trastuzumab and rituximab - ScienceDirect Comparison of two-dimensional gel electrophoresis patterns and MALDI-TOF MS analysis of therapeutic recombinant monoclonal antibodies trastuzumab and rituximab - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0731708511003785-gr2.jpg)
Comparison of two-dimensional gel electrophoresis patterns and MALDI-TOF MS analysis of therapeutic recombinant monoclonal antibodies trastuzumab and rituximab - ScienceDirect
![Sequence coverage obtained by CESI-MS/MS for trastuzumab (left-hand... | Download Scientific Diagram Sequence coverage obtained by CESI-MS/MS for trastuzumab (left-hand... | Download Scientific Diagram](https://www.researchgate.net/publication/269282654/figure/fig3/AS:669588631072777@1536653778715/Sequence-coverage-obtained-by-CESI-MS-MS-for-trastuzumab-left-hand-side-and.png)
Sequence coverage obtained by CESI-MS/MS for trastuzumab (left-hand... | Download Scientific Diagram
![A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients | Nature Communications A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-018-03537-w/MediaObjects/41467_2018_3537_Fig1_HTML.jpg)
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients | Nature Communications
![Trastuzumab Has Opposing Effects on SN-38-induced Double-strand Breaks and Cytotoxicity in HER2-positive Gastric Cancer Cells Depending on Administration Sequence | Anticancer Research Trastuzumab Has Opposing Effects on SN-38-induced Double-strand Breaks and Cytotoxicity in HER2-positive Gastric Cancer Cells Depending on Administration Sequence | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/32/1/105/F1.large.jpg)
Trastuzumab Has Opposing Effects on SN-38-induced Double-strand Breaks and Cytotoxicity in HER2-positive Gastric Cancer Cells Depending on Administration Sequence | Anticancer Research
![Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond: Trends in Cancer Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond: Trends in Cancer](https://www.cell.com/cms/attachment/2c4ed38b-36d5-464d-9b64-c8ff5bff5ac2/gr1.jpg)
Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond: Trends in Cancer
![Multiple alignment of the trastuzumab amino acid sequence by ClustalW... | Download Scientific Diagram Multiple alignment of the trastuzumab amino acid sequence by ClustalW... | Download Scientific Diagram](https://www.researchgate.net/publication/283003878/figure/fig2/AS:300347651313675@1448619868770/Multiple-alignment-of-the-trastuzumab-amino-acid-sequence-by-ClustalW-analysis-Four-mAb.png)
Multiple alignment of the trastuzumab amino acid sequence by ClustalW... | Download Scientific Diagram
![Frontiers | Effect of VH–VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA Binding Frontiers | Effect of VH–VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA Binding](https://www.frontiersin.org/files/MyHome%20Article%20Library/340080/340080_Thumb_400.jpg)
Frontiers | Effect of VH–VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA Binding
![Cancers | Free Full-Text | Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab Cancers | Free Full-Text | Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab](https://www.mdpi.com/cancers/cancers-15-02409/article_deploy/html/images/cancers-15-02409-g001.png)
Cancers | Free Full-Text | Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
![Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14) - The Lancet Gastroenterology & Hepatology Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14) - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/asset/4e90f133-b62f-443c-91cd-867eba87dedf/gr1.jpg)
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14) - The Lancet Gastroenterology & Hepatology
![CDR regions of Trastuzumab F(ab') 2 Light Chain and Heavy Chain Based... | Download Scientific Diagram CDR regions of Trastuzumab F(ab') 2 Light Chain and Heavy Chain Based... | Download Scientific Diagram](https://www.researchgate.net/publication/317043608/figure/fig5/AS:497238611894275@1495562331735/CDR-regions-of-Trastuzumab-Fab-2-Light-Chain-and-Heavy-Chain-Based-on-analysis-of-CDR.png)
CDR regions of Trastuzumab F(ab') 2 Light Chain and Heavy Chain Based... | Download Scientific Diagram
![JCI Insight - CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis JCI Insight - CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis](https://df6sxcketz7bb.cloudfront.net/manuscripts/131000/131882/medium/jci.insight.131882.f6.jpg)
JCI Insight - CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis
![Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond | Breast Cancer Management Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond | Breast Cancer Management](https://www.futuremedicine.com/cms/10.2217/bmt.12.35/asset/images/medium/figure1.gif)
Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond | Breast Cancer Management
![Cancers | Free Full-Text | T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer Cancers | Free Full-Text | T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer](https://www.mdpi.com/cancers/cancers-14-02468/article_deploy/html/images/cancers-14-02468-g0A5b.png)
Cancers | Free Full-Text | T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer
![Sequence by MALDI and ESI of Herceptin and 5G4 mAb. The proteolytic... | Download Scientific Diagram Sequence by MALDI and ESI of Herceptin and 5G4 mAb. The proteolytic... | Download Scientific Diagram](https://www.researchgate.net/publication/332994369/figure/fig1/AS:757043019403269@1557504529791/Sequence-by-MALDI-and-ESI-of-Herceptin-and-5G4-mAb-The-proteolytic-degradation-of-the.png)
Sequence by MALDI and ESI of Herceptin and 5G4 mAb. The proteolytic... | Download Scientific Diagram
![Optimize the combination regimen of Trastuzumab and Nab-paclitaxel in HER2-positive tumors via modulating Caveolin-1 expression by lovastatin - ScienceDirect Optimize the combination regimen of Trastuzumab and Nab-paclitaxel in HER2-positive tumors via modulating Caveolin-1 expression by lovastatin - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1818087622000642-ga1.jpg)
Optimize the combination regimen of Trastuzumab and Nab-paclitaxel in HER2-positive tumors via modulating Caveolin-1 expression by lovastatin - ScienceDirect
![Probing the interaction between cisplatin and the therapeutic monoclonal antibody trastuzumab - RSC Advances (RSC Publishing) DOI:10.1039/C6RA04337B Probing the interaction between cisplatin and the therapeutic monoclonal antibody trastuzumab - RSC Advances (RSC Publishing) DOI:10.1039/C6RA04337B](https://pubs.rsc.org/image/article/2016/RA/c6ra04337b/c6ra04337b-f3_hi-res.gif)